Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Antitumor drug therapy of lung cancer

ABSTRACT: Identification of the differentially expressed proteins

ORGANISM(S): Homo Sapiens

SUBMITTER: Yanxia Jin

PROVIDER: PXD052813 | iProX | Tue Jun 04 00:00:00 BST 2024

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Identification of lncRNAs Differentially Expressed in Basal-like Breast Cancer

Project description:Identification of lncRNAs Differentially Expressed in Basal-like Breast Cancer

| PRJNA488557 | ENA

Homo sapiens

Project description:Differentially expressed zinc finger proteins during human adipogenesis

| PRJNA163875 | ENA

comparative proteomics of non-small cell lung cancer and small cell lung cancer

Project description:We aimed to identify the differences between these two subtypes of lung cancers and their differentially clinical treatment. Through functional analysis, we obtained differentially expressed proteins which might be assossciated with lung cancer treatment.

2019-09-25 | PXD015270 | Pride

Identification of differentially expressed circRNAs in OLF

Project description:Identification of differentially expressed circRNAs in OLF

| PRJNA416002 | ENA

Identification of differentially expressed microRNAs in OLF

Project description:Identification of differentially expressed microRNAs in OLF

| PRJNA416005 | ENA

Project description:Identification of genes differentially expressed in cotton

| PRJNA99097 | ENA

Changes in Intestinal Flora and Serum Metabolites Pre- and Post-Antitumor Drug Therapy in Patients with Non-Small Cell Lung Cancer.

Project description:Objectivethis study aimed to identify the relationships between gut microbiota, metabolism, and non-small cell lung cancer (NSCLC) treatment outcomes, which are presently unclear.Methodsin this single-center prospective cohort study, we investigated changes in the gut microbiota and serum metabolite profile in 60 patients with NSCLC after four cycles of anticancer therapy.ResultsThe microbial landscape of the gut exhibited a surge in Proteobacteria and Verrucomicrobiota populations, alongside a decline in Firmicutes, Actinobacteriota, and Bacteroidota. Furthermore, a significant shift in the prevalence of certain bacterial genera was noted, with an increase in Escherichia/Shigella and Klebsiella, contrasted by a reduction in Bifidobacterium. Metabolomic analysis uncovered significant changes in lipid abundances, with certain metabolic pathways markedly altered post-treatment. Correlation assessments identified strong links between certain gut microbial genera and serum metabolite concentrations. Despite these findings, a subgroup analysis delineating patient responses to therapy revealed no significant shifts in the gut microbiome's composition after four cycles of treatment.ConclusionsThis study emphasizes the critical role of gut microbiota changes in NSCLC patients during anticancer treatment. These insights pave the way for managing treatment complications and inform future research to improve patient care by understanding and addressing these microbiota changes.

| S-EPMC10816336 | biostudies-literature

Transcriptome analysis on gastric cancer

Project description:Reliable identification of cancer markers can have substantial implications to early detection of cancer. We report here an integrated computational and experimental study on identification of gastric cancer markers in patients’ tissue and sera based on (i) genome-scale transcriptomic analyses on 80 paired gastric cancer/reference tissues, with the aim of identifying abnormally expressed genes at various subtypes/stages of gastric carcinoma (ii) a computational identification of differentially expressed genes that may have their proteins secreted into blood circulation, followed by experimental validations.

2011-03-01 | GSE27342 | GEO

Differentially expressed SE-lncRNAs in lung adenocarcinoma

Project description:Differentially expressed SE-lncRNAs in lung adenocarcinoma

| PRJNA805532 | ENA

Lung Cancer Drug resistance LC-MS/MS

Project description:In depth label free quantitative mass spectrometry based proteomics for identification of potential biomarkers of drug resistance in lung cancer.

2023-03-10 | PXD036996 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data